An Ingredient of Pot May Help People with Epilepsy

A new marijuana-derived drug may treat epileptic children, without the high

Join Our Community of Science Lovers!

A rising number of epileptic patients are using an alternative medicine to reduce their seizures. The herb in question is Cannabis sativa. Among the users are some of the almost 100,000 American children who have “intractable epilepsy,” which does not respond to standard antiseizure medications. Some parents report that marijuana helps to control their child's seizures when other standard drugs do not.

There is no pharmaceutical preparation of cannabis as a drug. Instead parents must personally buy pot at a medical marijuana dispensary—or perhaps illegally—to help their child.

The isolation of a chemical in marijuana that may be involved with tamping down seizures could soon change all that. Cannabidiol is a purified compound derived from cannabis that shows promise in treating epilepsy in both adults and children. The chemical, which also is responsible for some of the other health benefits associated with medical marijuana, is the main active ingredient in a new drug under investigation, called Epidiolex, manufactured by GW Pharmaceuticals. Epidiolex contains several other cannabinoid compounds but is formulated without tetrahydrocannabinol, the compound that makes people feel high.


On supporting science journalism

If you're enjoying this article, consider supporting our award-winning journalism by subscribing. By purchasing a subscription you are helping to ensure the future of impactful stories about the discoveries and ideas shaping our world today.


As with some approved seizure medications, researchers do not understand exactly how cannabidiol functions as an anticonvulsant. Whatever its physiological underpinnings, cannabidiol seems to work. Animal studies and preliminary investigations with human adults suggest it significantly reduces seizures and is well tolerated and safe.

Now researchers are making formal efforts to test cannabidiol in children with intractable epilepsy. A year-long clinical trial will test whether it diminishes epileptic activity in 150 children who have not been helped by standard seizure medications. If Epidiolex proves itself, it will supply additional evidence that marijuana may serve as a potential cornucopia of medical leads to be used for future drug development.

Annie Sneed is a science journalist who has written for the New York Times, Wired, Public Radio International and Fast Company.

More by Annie Sneed
Scientific American Magazine Vol 310 Issue 5This article was published with the title “Pot Ingredient for Epilepsy” in Scientific American Magazine Vol. 310 No. 5 (), p. 29
doi:10.1038/scientificamerican0514-29

It’s Time to Stand Up for Science

If you enjoyed this article, I’d like to ask for your support. Scientific American has served as an advocate for science and industry for 180 years, and right now may be the most critical moment in that two-century history.

I’ve been a Scientific American subscriber since I was 12 years old, and it helped shape the way I look at the world. SciAm always educates and delights me, and inspires a sense of awe for our vast, beautiful universe. I hope it does that for you, too.

If you subscribe to Scientific American, you help ensure that our coverage is centered on meaningful research and discovery; that we have the resources to report on the decisions that threaten labs across the U.S.; and that we support both budding and working scientists at a time when the value of science itself too often goes unrecognized.

In return, you get essential news, captivating podcasts, brilliant infographics, can't-miss newsletters, must-watch videos, challenging games, and the science world's best writing and reporting. You can even gift someone a subscription.

There has never been a more important time for us to stand up and show why science matters. I hope you’ll support us in that mission.

Thank you,

David M. Ewalt, Editor in Chief, Scientific American

Subscribe